HomeCompareARSUF vs KMB

ARSUF vs KMB: Dividend Comparison 2026

ARSUF yields 1.45% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARSUF wins by $17.15M in total portfolio value· pulled ahead in Year 4
10 years
ARSUF
ARSUF
● Live price
1.45%
Share price
$27.00
Annual div
$0.39
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17.20M
Annual income
$15,185,781.50
Full ARSUF calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — ARSUF vs KMB

📍 ARSUF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARSUFKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARSUF + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARSUF pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARSUF
Annual income on $10K today (after 15% tax)
$123.09/yr
After 10yr DRIP, annual income (after tax)
$12,907,914.28/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, ARSUF beats the other by $12,903,475.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARSUF + KMB for your $10,000?

ARSUF: 50%KMB: 50%
100% KMB50/50100% ARSUF
Portfolio after 10yr
$8.62M
Annual income
$7,595,501.92/yr
Blended yield
88.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

ARSUF
No analyst data
Altman Z
3.9
Piotroski
7/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARSUF buys
0
KMB buys
0
No recent congressional trades found for ARSUF or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARSUFKMB
Forward yield1.45%5.25%
Annual dividend / share$0.39$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%17%
Portfolio after 10y$17.20M$45.9K
Annual income after 10y$15,185,781.50$5,222.34
Total dividends collected$17.02M$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ARSUF vs KMB ($10,000, DRIP)

YearARSUF PortfolioARSUF Income/yrKMB PortfolioKMB Income/yrGap
1$10,990$289.63$11,314$614.45$324.00KMB
2$12,354$594.94$12,867$760.19$513.00KMB
3$14,469$1,250.08$14,713$945.27$244.00KMB
4← crossover$18,218$2,736.60$16,924$1,181.90+$1.3KARSUF
5$25,934$6,440.67$19,596$1,486.64+$6.3KARSUF
6$44,887$17,137.37$22,850$1,882.16+$22.0KARSUF
7$103,471$55,441.98$26,849$2,399.80+$76.6KARSUF
8$349,596$238,882.57$31,812$3,083.36+$317.8KARSUF
9$1,882,687$1,508,619.21$38,033$3,994.72+$1.84MARSUF
10$17,200,257$15,185,781.50$45,918$5,222.34+$17.15MARSUF

ARSUF vs KMB: Complete Analysis 2026

ARSUFStock

Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it supplies raw materials, utensils and equipment, semi-finished products, vehicles, and sterile and non-sterile compounded medicines. Further, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. It has operations in Latin America, North America, Europe, the Middle East, and Africa. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

Full ARSUF Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this ARSUF vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARSUF vs SCHDARSUF vs JEPIARSUF vs OARSUF vs KOARSUF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.